Valeritas, which markets a disposable device that delivers basal-bolus insulin therapy for Type 2 diabetes, withdrew its plans for an initial public offering on Thursday.
It had originally set terms in March 2015 to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the range, it would have commanded a market cap of $241 million. The company had not updated its filing since the IPO attempt.
